GWM
ALXN

Geneos Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Geneos Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-266
Closed -$44K – 3196
2021
Q1 		$44K Buy
+266
New +$41.1K ﹤0.01% 1706
2020
Q2 		– Sell
-22
Closed -$1K – 2652
2020
Q1 		$1K Sell
22
-8
-27% -$785 ﹤0.01% 2457
2019
Q4 		$3K Buy
+30
New +$3.21K ﹤0.01% 2339
2017
Q4 		– Sell
-67
Closed -$9K – 2233
2017
Q3 		$9K Buy
+67
New +$9.1K ﹤0.01% 1626
2016
Q4 		– Sell
-22
Closed -$2K – 2100
2016
Q3 		$2K Buy
22
+3
+16% +$386 ﹤0.01% 1834
2016
Q2 		$2K Hold
19
– – ﹤0.01% 1714
2016
Q1 		$2K Buy
+19
New +$2.79K ﹤0.01% 1703

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $7.94B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $4.65B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.37B AUM 63.08% 1-Year Est. Return